Pancreatic Cancer Research

ResearcherHeidelberg UniversityActive in the last 2 years

Albrecht Stenzinger

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1001-103X; OpenAlex author ID A5023136607, A5026607584, A5040766880. Sources: OpenAlex.

Their work

Papers
17 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
78
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: 3 papers · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 3 papers · 2026: 1 paper

Papers 17

  1. ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0138↗
  2. 17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing? Co-author DOI 10.1016/j.esmogo.2025.100218↗
  3. Characterization of single neurons reprogrammed by pancreatic cancer. Co-author DOI 10.1038/s41586-025-08735-3↗
  4. An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial. Co-author DOI 10.1186/s12943-025-02406-7↗
  5. Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients w… Co-author DOI 10.1111/cts.13661↗
  6. Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model. Co-author DOI 10.3389/fimmu.2022.1096162↗
  7. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-17-2180↗
  8. NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-18-0036↗
  9. A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pan… Co-author DOI 10.1186/s12885-017-3604-y↗
  10. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/nm.4038↗
  11. Ataxia-telangiectasia-mutated protein kinase levels stratify patients with pancreatic adenocarcinoma into prognostic subgroups with loss being a strong indicat… Last author DOI 10.1097/mpa.0000000000000248↗
  12. Allelic Ratio of KRAS Mutations in Pancreatic Cancer First author DOI 10.1634/theoncologist.2014-0408↗
  13. GOT1/AST1 expression status as a prognostic biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.2799↗
  14. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000077↗
  15. High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/1471-2407-13-450↗
  16. High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer. Co-author DOI 10.1111/j.1365-2559.2012.04225.x↗
  17. Postoperative complications deteriorate long-term outcome in pancreatic cancer patients. Co-author DOI 10.1245/s10434-011-2041-4↗

Closest collaborators

The 25 strongest of 78 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thomas Theodor Werner Seufferlein · 3 shared papers, 2023–2026 · strength 0.51
  2. Martin Ronald Sprick · 4 shared papers, 2016–2025 · strength 0.42
  3. Andreas Trumpp · 4 shared papers, 2016–2025 · strength 0.42
  4. Alexander Kleger · 2 shared papers, 2025–2026 · strength 0.37
  5. Jens Thomas Siveke · 2 shared papers, 2023–2025 · strength 0.33
  6. Christoph Springfeld · 4 shared papers, 2017–2023 · strength 0.30
  7. Wilko Weichert · 7 shared papers, 2012–2018 · strength 0.29
  8. Marcus Bahra · 7 shared papers, 2012–2018 · strength 0.27
  9. Thilo Hackert · 3 shared papers, 2016–2025 · strength 0.27
  10. Rui Fang · 1 shared paper, 2025 · strength 0.19
  11. Tim Eiseler · 1 shared paper, 2025 · strength 0.19
  12. Phyllis F. Cheung · 1 shared paper, 2025 · strength 0.19
  13. Andrea Tannapfel · 1 shared paper, 2025 · strength 0.19
  14. Thomas Jens Ettrich · 1 shared paper, 2025 · strength 0.19
  15. Anton Lahusen · 1 shared paper, 2025 · strength 0.19
  16. Meinolf Karthaus · 1 shared paper, 2025 · strength 0.19
  17. Manfred Paul Lutz · 1 shared paper, 2025 · strength 0.19
  18. Christine E. Engeland · 2 shared papers, 2017–2022 · strength 0.19
  19. Guy Ungerechts · 2 shared papers, 2017–2022 · strength 0.19
  20. Jacek Hajda · 2 shared papers, 2017–2023 · strength 0.19
  21. Claudia R. Ball · 2 shared papers, 2018–2022 · strength 0.19
  22. Bruno Valentin Sinn · 5 shared papers, 2012–2016 · strength 0.18
  23. Rienk Offringa · 1 shared paper, 2025 · strength 0.18
  24. Alexander Muckenhuber · 4 shared papers, 2013–2018 · strength 0.18
  25. Vera Thiel · 1 shared paper, 2025 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.